Display options
Cite
Mosci C, Iagaru A. (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clin. 2012;7(3):263-74doi: 10.1016/j.cpet.2012.04.003.
Mosci, C., & Iagaru, A. (2012). (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET clinics, 7(3), 263-74. https://doi.org/10.1016/j.cpet.2012.04.003
Mosci, Camila, and Iagaru, Andrei. "(18)F NaF PET/CT in the Assessment of Malignant Bone Disease." PET clinics vol. 7,3 (2012): 263-74. doi: https://doi.org/10.1016/j.cpet.2012.04.003
Mosci C, Iagaru A. (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clin. 2012 Jul;7(3):263-74. doi: 10.1016/j.cpet.2012.04.003. Epub 2012 May 24. PMID: 27157457.
Copy Download .nbib Format: NLM
Share it on

PET Clin. 2012 Jul;7(3):263-74. doi: 10.1016/j.cpet.2012.04.003. Epub 2012 May 24.

(18)F NaF PET/CT in the Assessment of Malignant Bone Disease.

PET clinics

Camila Mosci, Andrei Iagaru

Affiliations

  1. Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, H-2200, Stanford, CA 94305-5281, USA.

PMID: 27157457 DOI: 10.1016/j.cpet.2012.04.003

Abstract

Diagnostic imaging plays a major role in the evaluation of patients with malignant bone disease. (18)F-Labeled sodium fluoride ((18)F NaF) is a positron-emitting radiopharmaceutical with desirable characteristics (rapid blood clearance and bone uptake) for high-quality functional imaging of the skeleton. In addition to higher sensitivity and specificity, (18)F NaF PET combined with computed tomography (PET/CT) allows for shorter imaging time, thus improving patients' convenience and benefiting the overall workflow of the imaging facility. Although as yet no robust evidence-based data exist, this article summarizes the published data currently available on the role of (18)F NaF PET/CT in the assessment of malignant bone disease.

Copyright © 2012 Elsevier Inc. All rights reserved.

Publication Types